1
|
Ibrahim R, Saleh K, Khoury R, Khalife N, Chahine C, Cesne AL. Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer. Future Oncol 2024; 20:55-58. [PMID: 38193281 DOI: 10.2217/fon-2023-0523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2024] Open
Affiliation(s)
- Rebecca Ibrahim
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Khalil Saleh
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Rita Khoury
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Nadine Khalife
- Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Axel Le Cesne
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| |
Collapse
|
2
|
Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Lecesne A. KRASG12C mutation in metastatic colorectal cancer: a new target. Future Oncol 2023; 19:1641-1643. [PMID: 37602398 DOI: 10.2217/fon-2023-0223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/22/2023] Open
Affiliation(s)
- Rebecca Ibrahim
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Khalil Saleh
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Rita Khoury
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Nadine Khalife
- Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Axel Lecesne
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| |
Collapse
|
3
|
Willekens C, Chahine C, Dragani M, Khalife‐Hachem S, Bigenwald C, Rossignol J, Castilla‐Llorente C, Danu A, Michot J, Saada V, Cotteret S, Marzac C, Renneville A, Plo I, Broutin S, Bosselut N, Cassinat B, Lazarovici J, Droin N, De Botton S. When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes. EJHaem 2023; 4:823-826. [PMID: 37601857 PMCID: PMC10435719 DOI: 10.1002/jha2.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 05/10/2023] [Accepted: 05/10/2023] [Indexed: 08/22/2023]
Affiliation(s)
- Christophe Willekens
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
- Inserm U1287Gustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Claude Chahine
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Matteo Dragani
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | | | - Camille Bigenwald
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Julien Rossignol
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | | | - Alina Danu
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Jean‐Marie Michot
- Département d'Innovation Thérapeutique et d'Essais PrécocesGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Veronique Saada
- Département de Biologie et Pathologie MédicalesGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Sophie Cotteret
- Département de Biologie et Pathologie MédicalesGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Christophe Marzac
- Département de Biologie et Pathologie MédicalesGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Aline Renneville
- Inserm U1287Gustave RoussyUniversité Paris‐SaclayVillejuifFrance
- Département de Biologie et Pathologie MédicalesGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Isabelle Plo
- Inserm U1287Gustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Sophie Broutin
- Département de Biologie et Pathologie MédicalesGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Nelly Bosselut
- AP‐HPHôpital Saint‐Louis, Service de Biologie CellulaireParisFrance
| | - Bruno Cassinat
- AP‐HPHôpital Saint‐Louis, Service de Biologie CellulaireParisFrance
| | - Julien Lazarovici
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Nathalie Droin
- Inserm U1287Gustave RoussyUniversité Paris‐SaclayVillejuifFrance
| | - Stephane De Botton
- Département d'HématologieGustave RoussyUniversité Paris‐SaclayVillejuifFrance
| |
Collapse
|
4
|
Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Cesne AL. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy. Biomedicines 2023; 11:1878. [PMID: 37509517 PMCID: PMC10377063 DOI: 10.3390/biomedicines11071878] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 06/25/2023] [Accepted: 06/28/2023] [Indexed: 07/30/2023] Open
Abstract
One of the most important steps forward in the management of cancer was the discovery of immunotherapy. It has become an essential pillar in the treatment paradigm of cancer patients. Unfortunately, despite the various options presented with immune checkpoint inhibitors (ICIs), the benefit is still limited to select patients and the vast majority of these patients gain either minimal benefit or eventually progress, leaving an unmet need for the development of novel therapeutic agents and strategies. Lymphocyte activation gene-3 (LAG-3), an immune checkpoint receptor protein, is a molecule found on the surface of activated T-cells. It plays a major role in negatively regulating T-cell function thereby providing tumors with an immune escape in the tumor microenvironment (TME). Given its importance in regulating the immune system, LAG-3 has been considered as a promising target in oncology and precision medicine. To date, two LAG-3-directed agents (eftilagimod alpha and relatlimab) have been approved in combination with programmed death-1 (PD-1) inhibitors in the setting of advanced solid tumors. In this review, we discuss the structure of LAG-3, its mechanism of action, and its interaction with its ligands. We also shed light on the emerging treatments targeting LAG-3 for the treatment of solid tumors.
Collapse
Affiliation(s)
- Rebecca Ibrahim
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Khalil Saleh
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Rita Khoury
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Nadine Khalife
- Department of head and neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Axel Le Cesne
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| |
Collapse
|
5
|
Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci 2023; 24:ijms24119674. [PMID: 37298631 DOI: 10.3390/ijms24119674] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 05/29/2023] [Accepted: 05/30/2023] [Indexed: 06/12/2023] Open
Abstract
The treatment of cancer patients has dramatically changed over the past decades with the advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and innovative T-cell therapy. Antibody-drug conjugates (ADCs) have also revolutionized the treatment of cancer. Several ADCs have already been approved in hematology and clinical oncology, such as trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG) for the treatment of metastatic breast cancer, and enfortumab vedotin (EV) for the treatment of urothelial carcinoma. The efficacy of ADCs is limited by the emergence of resistance due to different mechanisms, such as antigen-related resistance, failure of internalization, impaired lysosomal function, and other mechanisms. In this review, we summarize the clinical data that contributed to the approval of T-DM1, T-DXd, SG, and EV. We also discuss the different mechanisms of resistance to ADCs, as well as the ways to overcome this resistance, such as bispecific ADCs and the combination of ADCs with immune-checkpoint inhibitors or tyrosine-kinase inhibitors.
Collapse
Affiliation(s)
- Rita Khoury
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Khalil Saleh
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Nadine Khalife
- Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Mohamad Saleh
- Department of Hematology and Oncology, Lebanese American University Medical Center-Rizk Hopsital, Beirut 1100, Lebanon
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Rebecca Ibrahim
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| | - Axel Lecesne
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France
| |
Collapse
|
6
|
Khoury R, Chahine C, Ibrahim R, Khalife N, Saleh M, Saleh K. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma. Future Oncol 2023; 19:1161-1163. [PMID: 37293779 DOI: 10.2217/fon-2023-0318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Open
Affiliation(s)
- Rita Khoury
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Rebecca Ibrahim
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Nadine Khalife
- Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Mohammad Saleh
- Department of Hematology & Oncology, Lebanese American University Medical Center-Rizk Hopsital, Beirut, 11-3288, Lebanon
| | - Khalil Saleh
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| |
Collapse
|
7
|
Affiliation(s)
- Rebecca Ibrahim
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Tony Felefly
- Radiation Oncology Department, Saint-Joseph University, Beyrouth, 1100, Lebanon
| | - Nadine Khalife
- Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Khalil Saleh
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| |
Collapse
|
8
|
Assi T, Ibrahim T, Chahine C, Lezghed N, Masri N, Rouleau E, Caron O, Le Cesne A. 91P Liquid biopsy, a tool to detect genetic alterations with therapeutic impact in international patients: Prospective data on 47 patients from Gustave Roussy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Abstract
Bladder cancer is the seventh most frequent cancer worldwide. The majority of patients present with nonmuscle invasive disease, while 20% of the patients are diagnosed with muscle-invasive bladder cancer. The treatment of nonmuscle invasive disease is endoscopic resection followed by intravesical adjuvant treatment for high risk patients. The standard treatment of localized muscle-invasive disease is neoadjuvant chemotherapy followed by radical cystectomy. Platinum-based chemotherapy is the first-line treatment in locally advanced or metastatic urothelial carcinoma. Immune checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma as second-line treatment or first-line in platinum-ineligible patients. Recently, pembrolizumab have been approved in bacillus Calmette-Guérin (BCG)-refractory nonmuscle invasive bladder cancer. This review summarizes the current evidence concerning immunotherapy in the treatment of urothelial carcinoma.
Collapse
Affiliation(s)
- Nadine Khalife
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Manal Kordahi
- National Institute of Pathology, Baabda, 1003, Lebanon
| | - Tony Felefly
- Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon
| | - Hampig Raphael Kourie
- Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1100, Lebanon
| | - Khalil Saleh
- Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| |
Collapse
|
10
|
Michot JM, Buet-Elfassy A, Annereau M, Lazarovici J, Danu A, Sarkozy C, Chahine C, Bigenwald C, Bosq J, Rossignol J, Romano-Martin P, Baldini C, Ghez D, Dartigues P, Massard C, Ribrag V. Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma. Cancer Drug Resist 2021; 4:710-718. [PMID: 35582306 PMCID: PMC9094080 DOI: 10.20517/cdr.2020.109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Revised: 02/14/2021] [Accepted: 02/25/2021] [Indexed: 11/29/2022]
Abstract
Aim: Anti-CD20 monoclonal antibody is a cornerstone therapy for follicular lymphoma. Following anti-CD20 therapy, a potential decrease in CD20 antigen, and therefore a loss of the tumor target might be expected. However, the incidence and clinical significance of CD20 loss on tumor cells in patients with relapsed or refractory follicular lymphoma are unknown. This study aims to investigate the incidence and outcome of patients with relapsed or refractory follicular lymphoma patients harboring the loss of the tumor target, CD20. Methods: All consecutive adult patients with relapsed or refractory follicular lymphoma referred to the Early Drug Department at Gustave Roussy were included. The main objectives were to assess the incidence and prognosis of the loss in expression of CD20 antigen on the surface of tumor cells on patient outcome. Results: Over the study period 2013-2018, 131 patients were screened for clinical trials with B-cell malignancies in the early drug department of Gustave Roussy in France. Forty-four patients presented with relapsed or refractory follicular lymphoma and 32 had tumor biopsies at the time of relapse that were retained for analysis. The median (range) age was 67.5 years (55.3-75.3) and the median number of prior anti-cancer systemic therapies was 3 (2-4). At the time of relapse, CD20 expression was positive in 84% of tumors (n = 27) and negative in 16% of tumors (n = 5). At a median follow-up of 18.3 (0.6-83.3) months, CD20 negativity was associated with a poorer prognosis with a median overall survival of 8.9 months (95%CI: 2.4-19.1) in comparison to CD20 positive patients (28.3 months, 95%CI: 25.1-75.3 months, P = 0.019). Conclusion: The loss of the tumor target antigen, CD20, occurred in 16% of patients with relapse or refractory follicular lymphoma. Due to confounding factors in patients who received anti-CD20 immunotherapy, it was not possible to formally establish the prognostic significance of CD20 negativity. However, we suggest that a check for CD20 antigen positivity nevertheless be performed to adapt subsequent therapies for patients with relapsed or refractory follicular lymphoma.
Collapse
Affiliation(s)
- Jean-Marie Michot
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif 94800, France
| | - Alice Buet-Elfassy
- Gustave Roussy, Université Paris-Saclay, Pharmacy Departement, Villejuif 94800, France
| | - Maxime Annereau
- Gustave Roussy, Université Paris-Saclay, Pharmacy Departement, Villejuif 94800, France
| | - Julien Lazarovici
- Gustave Roussy, Université Paris-Saclay, Departement of Hematology, Villejuif 94800, France
| | - Alina Danu
- Gustave Roussy, Université Paris-Saclay, Departement of Hematology, Villejuif 94800, France
| | - Clémentine Sarkozy
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif 94800, France
| | - Claude Chahine
- Gustave Roussy, Université Paris-Saclay, Departement of Hematology, Villejuif 94800, France
| | - Camille Bigenwald
- Gustave Roussy, Université Paris-Saclay, Departement of Hematology, Villejuif 94800, France
| | - Jacques Bosq
- Gustave Roussy, Université Paris-Saclay, Departement of Pathology, Villejuif 94800, France
| | - Julien Rossignol
- Gustave Roussy, Université Paris-Saclay, Departement of Hematology, Villejuif 94800, France
| | - Patricia Romano-Martin
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif 94800, France
| | - Capucine Baldini
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif 94800, France
| | - David Ghez
- Gustave Roussy, Université Paris-Saclay, Departement of Hematology, Villejuif 94800, France
| | - Peggy Dartigues
- Gustave Roussy, Université Paris-Saclay, Departement of Pathology, Villejuif 94800, France
| | - Christophe Massard
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif 94800, France
| | - Vincent Ribrag
- Gustave Roussy, Université Paris-Saclay, Departement of Hematology, Villejuif 94800, France
| |
Collapse
|
11
|
Saleh K, Chahine C, Khalife N. Chemotherapy-free regimen: a new hope in Philadelphia-positive acute lymphoblastic leukemia. Future Oncol 2021; 17:1265-1267. [PMID: 33573414 DOI: 10.2217/fon-2020-1220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Khalil Saleh
- Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Claude Chahine
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - Nadine Khalife
- Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| |
Collapse
|
12
|
Chahine C, Roos-Weil D, Saada V, de Botton S, Micol JB, Barete S, Marzac C, Ghez D. Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk 2020; 20:e986-e989. [PMID: 32917576 DOI: 10.1016/j.clml.2020.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 06/23/2020] [Accepted: 08/02/2020] [Indexed: 10/23/2022]
Affiliation(s)
- Claude Chahine
- Department of Hematology, Gustave Roussy, Cancer Campus, Villejuif, France
| | - Damien Roos-Weil
- Department of Hematology, Hôpital de la Pitié Salpetriere, Paris, France
| | - Véronique Saada
- Department of Biology, Gustave Roussy, Cancer Campus, Villejuif, France
| | - Stéphane de Botton
- Department of Hematology, Gustave Roussy, Cancer Campus, Villejuif, France
| | | | - Stéphane Barete
- Department of Dermatology, Hôpital de la Pitié Salpetriere, Paris, France
| | - Christophe Marzac
- Department of Biology, Gustave Roussy, Cancer Campus, Villejuif, France
| | - David Ghez
- Department of Hematology, Gustave Roussy, Cancer Campus, Villejuif, France.
| |
Collapse
|
13
|
Pasquier F, Chahine C, Marzac C, de Botton S. Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Expert Review of Precision Medicine and Drug Development 2020. [DOI: 10.1080/23808993.2020.1792286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Florence Pasquier
- Department of Clinical, Gustave Roussy Cancer Center, Villejuif, France
| | - Claude Chahine
- Department of Clinical, Gustave Roussy Cancer Center, Villejuif, France
| | - Christophe Marzac
- Department of Biopathology, Gustave Roussy Cancer Center, Villejuif, France
| | - Stéphane de Botton
- Department of Clinical, Gustave Roussy Cancer Center, Villejuif, France
- Department of Therapeutic Innovations and Early Trials (DITEP), Gustave Roussy Cancer Center, Villejuif, France
- Department of Hematology, INSERM U1170, Gustave Roussy, Paris-Saclay University, Villejuif, France
- Department of Hematology, Paris-Sud University, Kremlin-Bicêtre, France
| |
Collapse
|
14
|
Saleh K, Michot JM, Schernberg A, Lazarovici J, Chahine C, Danu A, Khalife-Saleh N, Rossignol J, Ghez D, Martin V, Mazeron R, Fermé C, Boros A, Ribrag V, Girinsky T. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. Cancer Med 2020; 9:3725-3732. [PMID: 32249547 PMCID: PMC7286454 DOI: 10.1002/cam4.2796] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2019] [Revised: 11/09/2019] [Accepted: 12/06/2019] [Indexed: 11/12/2022] Open
Abstract
Purpose In patients with indolent B‐cell non‐Hodgkin's lymphoma (B‐NHL), one course of low‐dose radiotherapy (LD‐RT) 2 × 2 Gy is emerging as new option of therapy in palliative setting. Efficacy of LD‐RT when repeated remains to be determinate. This study aims to assess the efficacy of repeated LD‐RT given in patients with indolent B‐NHL. Materials and Methods All consecutive adult patients who received two or more courses of LD‐RT 2 × 2 Gy for indolent B‐NHL at Gustave Roussy institution, during the period 1990‐2015 were retrospectively investigated. Results Thirty‐three patients received two or more courses of LD‐RT for indolent B‐NHL during the study period. The median age was 57 (range 37‐80) years, histological types were distributed among follicular lymphoma (n = 24 pts; 73%), marginal‐zone lymphoma (n = 6 pts; 18%), and primary cutaneous follicle center lymphoma (n = 3 pts; 9%). The median number of low‐dose radiation therapy courses given per patients was 2 (range 2‐6). The overall response rates following the first and the second course of LD‐RT were 96% and 88%, respectively (P = .31). The 1‐ and 2‐years local control rates following the first courses of LD‐RT were 94% (CI 95: 86‐100) and 94% (CI 95: 86‐98); and were 91% (CI 95: 82‐100) and 88% (CI 95: 77‐100) following the second course of LD‐RT (P = .39). Conclusion The repeated courses of LD‐RT offered similar efficacy compare with the first course in patients with indolent B‐NHL. LD‐RT repeated is a simple, easy to give, and non‐toxic asset that could be investigated as treatment option in patients with indolent B‐NHL.
Collapse
Affiliation(s)
- Khalil Saleh
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jean-Marie Michot
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Drug Development Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Antoine Schernberg
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Julien Lazarovici
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Claude Chahine
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Alina Danu
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Nadine Khalife-Saleh
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Julien Rossignol
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - David Ghez
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Valentine Martin
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Renaud Mazeron
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Christophe Fermé
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Angela Boros
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Vincent Ribrag
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Drug Development Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
15
|
Michot JM, Annereau M, Danu A, Legoupil C, Bertin L, Chahine C, Achab N, Antosikova A, Cerutti A, Rossignol J, Ghez D, Willekens C, Dartigues P, Lazarovici J, Lemare F, Ribrag V. High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result. Eur J Haematol 2020; 104:281-290. [PMID: 31838764 DOI: 10.1111/ejh.13369] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2019] [Revised: 12/05/2019] [Accepted: 12/11/2019] [Indexed: 12/27/2022]
Abstract
BACKGROUND High-dose cyclophosphamide to treat solid refractory tumors demonstrated meaningful activity, while data to treat lymphoma remain scarce. This study aims to assess high-dose cyclophosphamide to treat relapsed or refractory lymphoma. METHODS A phase II study included adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, previously treated by ≥2 prior lines with no other available option of therapy. High-dose cyclophosphamide was given intravenously 3 g/m2 over two consecutive days and repeated once at 28 days in responding patients. Rituximab 375 mg/m2 intravenously was added in patients not refractory to anti-CD20 antibody. RESULTS Forty-two patients with median age 65 [56-70] years were included. Patients had previously received a median of four lines of therapies. Tumor types were diffuse large B-cell lymphoma (n = 26; 62%), indolent B-cell non-Hodgkin lymphoma (n = 10; 24%), or mantle lymphoma (n = 6; 14%). Hematologic and non-hematologic grade 3-5 toxicities occurred in 42 (100%) and 18 (43%) of patients, respectively. The overall response rate was 45%. CONCLUSION One to two cycles of high-dose cyclophosphamide in hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated a favorable safety and efficacy profile. This regimen could serve as a bridge to modern cellular therapy with CAR-T cell.
Collapse
Affiliation(s)
- Jean-Marie Michot
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Maxime Annereau
- Pharmacy, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Alina Danu
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Clémence Legoupil
- Pharmacy, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Oncostat, INSERM U1018, Centre de recherche en épidémiologie et santé des populations, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Louis Bertin
- Pharmacy, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Claude Chahine
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Nadia Achab
- Pharmacy, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Anna Antosikova
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Ariane Cerutti
- Pharmacy, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Julien Rossignol
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - David Ghez
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Christophe Willekens
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Peggy Dartigues
- Département de Pathologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Julien Lazarovici
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Francois Lemare
- Pharmacy, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Vincent Ribrag
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
16
|
Michot J, Camara-Clayette V, Detolle A, Chahine C, Lazarovici J, Danu A, Bosq J, Ghez D, Romano-Martin P, Dartigues P, Arfi-Rouche J, Bahleda R, Rahali W, Varga A, Baldini C, Tselikas L, Paume C, Lecourt H, Cotteret S, Vergé V, Soria J, Massard C, Ribrag V. FEASIBILITY AND BENEFIT OF MOLECULARLY-INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.142_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Michot
- Hematology; Gustave Roussy; Villejuif France
| | | | - A. Detolle
- Hematology; Gustave Roussy; Villejuif France
| | - C. Chahine
- Hematology; Gustave Roussy; Villejuif France
| | | | - A. Danu
- Hematology; Gustave Roussy; Villejuif France
| | - J. Bosq
- Hematology; Gustave Roussy; Villejuif France
| | - D. Ghez
- Hematology; Gustave Roussy; Villejuif France
| | | | | | | | - R. Bahleda
- Hematology; Gustave Roussy; Villejuif France
| | - W. Rahali
- Hematology; Gustave Roussy; Villejuif France
| | - A. Varga
- Drug Development Department; Gustave Roussy; Villejuif France
| | - C. Baldini
- Drug Development Department; Gustave Roussy; Villejuif France
| | - L. Tselikas
- Drug Development Department; Gustave Roussy; Villejuif France
| | - C. Paume
- Drug Development Department; Gustave Roussy; Villejuif France
| | - H. Lecourt
- Drug Development Department; Gustave Roussy; Villejuif France
| | - S. Cotteret
- Hematology; Gustave Roussy; Villejuif France
| | - V. Vergé
- Hematology; Gustave Roussy; Villejuif France
| | - J. Soria
- Drug Development Department; Gustave Roussy; Villejuif France
| | - C. Massard
- Drug Development Department; Gustave Roussy; Villejuif France
| | - V. Ribrag
- Hematology; Gustave Roussy; Villejuif France
| |
Collapse
|
17
|
Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2018; 6:e48-e57. [PMID: 30528137 DOI: 10.1016/s2352-3026(18)30175-3] [Citation(s) in RCA: 161] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2018] [Revised: 09/29/2018] [Accepted: 10/02/2018] [Indexed: 01/31/2023]
Abstract
BACKGROUND Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related adverse events (irAEs). These adverse events can involve all organs, including the haemopoietic system. Thus far, haematological irAEs (haem-irAEs) have not been extensively characterised. This study aims to provide a comprehensive report of the haem-irAEs induced by anti-PD-1 or anti-PD-L1. METHODS In this descriptive observational study, we included consecutive patients aged at least 18 years with grade 2 or worse haem-irAEs induced by anti-PD-1 or anti-PD-L1 immunotherapy registered in three French pharmacovigilance databases: the Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC; a prospective registry of patients treated with anti-PD-1 or anti-PD-L1 at a single centre), the ImmunoTOX committee of Gustave Roussy (a national referral database of suspected irAEs in patients treated with immunotherapy), and the registry of the Centre de Référence des Cytopénies Auto-Immunes de l'Adulte (CeReCAI; a national database of autoimmune cytopenias). Cases were reviewed by a central committee; adverse events had to be classed as certainly or probably related to anti-PD-1 or anti-PD-L1 therapy, and their severity was assessed according to the Common Terminology Criteria for Adverse Events (version 4.03). The primary endpoint was clinical description of haem-irAEs, as reported in all databases, and their frequency, as reported in the prospective REISAMIC registry. FINDINGS We screened 948 patients registered in the three databases from June 27, 2014, to June 29, 2018 (745 from REISAMIC, 190 from the ImmunoTOX committee, and 13 from CeReCAI). 35 patients (21 men and 14 women) with haem-irAEs related to anti-PD-1 or anti-PD-L1 were included in the study. Of 745 patients in the REISAMIC registry treated with anti-PD-1 or anti-PD-L1, four had haem-irAEs, giving a frequency of 0·5%. Median age in the 35 patients was 65 years (IQR 51-75), and the most common tumour types were melanoma (15 [43%] patients), non-small-cell lung cancer (12 [34%] patients), and lymphoma (four [11%] patients). 20 (57%) patients received nivolumab, 14 (40%) received pembrolizumab, and one (3%) received atezolizumab. Among the 35 patients, neutropenia, autoimmune haemolytic anaemia, and immune thrombocytopenia were the most common types of haem-irAE (each in nine patients [26%]), followed by pancytopenia or aplastic anaemia (five patients [14%]), bicytopenia (one patients with thrombocytopenia plus anaemia and one patient with neutropenia plus anaemia [6%]), and pure red cell aplasia (one patient [3%]). The maximum grade of severity was grade 2 in three (9%) patients, grade 3 in five (14%) patients, and grade 4 in 25 (71%) patients; two (6%) patients died from febrile neutropenia during haem-irAE related to anti-PD-1. Haem-irAEs resolved in 21 (60%) of the 35 patients. INTERPRETATION Haem-irAEs induced by PD-1 or PD-L1 inhibitors are rare but potentially life-threatening events. The most common clinical presentations are neutropenia, autoimmune haemolytic anaemia, immune thrombocytopenia, and aplastic anaemia. Investigations into earlier detection and better management are warranted. FUNDING Gustave Roussy and Gustave Roussy Immunotherapy Program.
Collapse
Affiliation(s)
- Nicolas Delanoy
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jean-Marie Michot
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Service de Médecine Interne and Immunologie Clinique, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
| | - Thibault Comont
- Service de Médecine Interne et d'Immunopathologie, Institut Universitaire du Cancer, Toulouse, France
| | - Nora Kramkimel
- Service de Dermatologie et Vénérologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Julien Lazarovici
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Romain Dupont
- Service de Médecine Interne et d'Immunopathologie, Institut Universitaire du Cancer, Toulouse, France
| | - Stéphane Champiat
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Claude Chahine
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Caroline Robert
- Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Charles Herbaux
- Service d'Hématologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Benjamin Besse
- Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Aude Guillemin
- Service d'Oncologie, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Christine Mateus
- Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Patricia Pautier
- Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Philippe Saïag
- Service des Cancers Cutanés, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Emanuela Madonna
- Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Marie Maerevoet
- Department of Haematology, Institute Jules Bordet, Brussels, Belgium
| | | | - Charlotte Leduc
- Service d'Oncologie Thoracique, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Pascal Biscay
- Service de Médecine Interne, Clinique Mutualiste de Pessac, Pessac, France
| | - Gilles Quere
- Service de Pneumologie, Hôpital Morvan Centre Hospitalier Régional Universitaire de Brest, Brest, France
| | - Charlée Nardin
- Service de Dermatologie, Centre Hospitalier Régional Universitaire Jean Minjoz, Besançon, France
| | - Mikael Ebbo
- Service de Médecine Interne, Hôpital de la Timone, Aix Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Laurence Albigès
- Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Grégoire Marret
- Service d'Oncologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Virginie Levrat
- Service de Pneumologie, Centre Hospitalier de La Rochelle, La Rochelle, France
| | - Cécile Dujon
- Service de Pneumologie, Hôpital André Mignot, Centre Hospitalier Universitaire de Versailles, Le Chesnay, France
| | - Jacques Vargaftig
- Service d'Hématologie, René Huguenin Hospital-Curie Institute, Saint-Cloud, France
| | - Salim Laghouati
- Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Laure Croisille
- Laboratoire HLA-ILP, Etablissement Français du Sang, Créteil, France
| | - Anne-Laure Voisin
- Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Bertrand Godeau
- Service de Médecine Interne, Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Christophe Massard
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Vincent Ribrag
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Aurélien Marabelle
- Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Marc Michel
- Service de Médecine Interne, Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Olivier Lambotte
- Service de Médecine Interne and Immunologie Clinique, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France; Université Paris Sud, Centre de Recherche en Immunologie des Infections Virales et des Maladies Auto-Immunes, INSERM, Le Kremlin-Bicêtre, France; Division d'Immunovirologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Fontenay-aux-Roses, France
| |
Collapse
|
18
|
Michot J, Camara-Clayette V, Chahine C, Lazarovici J, Bosq J, Ghez D, Dartigues P, Danu A, Arfi-Rouche J, Tselikas L, Ba B, Cotteret S, Rahali W, Vergé V, Ribrag V. Molecular landscape of relapse/refractory diffuse large B-cell lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- J. Michot
- Hematology; Gustave Roussy; Villejuif France
| | - V. Camara-Clayette
- Transfert Laboratory in Hematological Malignancies; Gustave Roussy; Villejuif France
| | - C. Chahine
- Hematology; Gustave Roussy; Villejuif France
| | | | - J. Bosq
- Pathology Laboratory; Gustave Roussy; Villejuif France
| | - D. Ghez
- Hematology; Gustave Roussy; Villejuif France
| | - P. Dartigues
- Pathology Laboratory; Gustave Roussy; Villejuif France
| | - A. Danu
- Hematology; Gustave Roussy; Villejuif France
| | - J. Arfi-Rouche
- Interventational Radiology; Gustave Roussy; Villejuif France
| | - L. Tselikas
- Interventational Radiology; Gustave Roussy; Villejuif France
| | - B. Ba
- Interventational Radiology; Gustave Roussy; Villejuif France
| | - S. Cotteret
- Hematology and Molecular Laboratories; Gustave Roussy; Villejuif France
| | - W. Rahali
- Hematology; Gustave Roussy; Villejuif France
| | - V. Vergé
- Hematology; Gustave Roussy; Villejuif France
| | - V. Ribrag
- Hematology; Gustave Roussy; Villejuif France
| |
Collapse
|
19
|
Annereau M, Willekens C, El Halabi L, Chahine C, Saada V, Auger N, Danu A, Bermudez E, Lazarovici J, Ghez D, Leary A, Pistilli B, Lemare F, Solary E, de Botton S, Desmaris RP, Micol JB. Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. Leuk Res 2017; 55:58-64. [PMID: 28131982 DOI: 10.1016/j.leukres.2017.01.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Revised: 10/31/2016] [Accepted: 01/17/2017] [Indexed: 10/20/2022]
Abstract
BACKGROUND Patients diagnosed with therapy-related myeloid neoplasms (TRMN) with concomitant active neoplastic disorder (CAND) are usually proposed for best supportive care (BSC). We evaluated the feasibility of using 5-azacytidine (AZA) in this setting. METHODS All patients referred to Gustave Roussy between 2010 and 2015 for TRMN diagnosis (less than 30% blast) and eligible for AZA treatment were included. Patients with CAND proposed for BSC were also described. Patient's outcomes were analyzed based on the presence or not of a CAND. RESULTS Fifty-two patients with TRMN were analyzed, including 19 patients with CAND (14 eligible for AZA) and 33 without CAND eligible for AZA. The 5 patients with CAND ineligible for AZA had a worst performance status (p=0.016) at diagnosis and a shorter overall survival (OS) (0.62 months). Baseline characteristics of patients eligible for AZA were similar in the 2 groups except a trend for best performance status in patients with CAND (p=0.06). Overall response rate (71.4% vs 60.3%), transfusion independence (50.0% vs 45.5%) and OS (12.7 months vs 10.8 months) were similar between patients with and without CAND respectively (p=ns). CONCLUSION Here we report the feasibility and efficacy of AZA for selected patients with TRMN and a CAND.
Collapse
Affiliation(s)
- M Annereau
- Gustave Roussy, Université Paris-Saclay, Département de Pharmacie, Villejuif F-94805, France
| | - C Willekens
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France
| | - L El Halabi
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France
| | - C Chahine
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France
| | - V Saada
- Gustave Roussy, Université Paris-Saclay, Département de biologie et pathologie médicales, Villejuif F-94805, France
| | - N Auger
- Gustave Roussy, Université Paris-Saclay, Département de biologie et pathologie médicales, Villejuif F-94805, France
| | - A Danu
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France
| | - E Bermudez
- Gustave Roussy, Université Paris-Saclay, Département de Pharmacie, Villejuif F-94805, France
| | - J Lazarovici
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France
| | - D Ghez
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France
| | - A Leary
- Gustave Roussy, Université Paris-Saclay, Département de médecine oncologique, Villejuif F-94805, France
| | - B Pistilli
- Gustave Roussy, Université Paris-Saclay, Département de médecine oncologique, Villejuif F-94805, France
| | - F Lemare
- Gustave Roussy, Université Paris-Saclay, Département de Pharmacie, Villejuif F-94805, France
| | - E Solary
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France; Inserm UMR1170, Gustave Roussy, Université Paris-Saclay, Villejuif F-94805, France
| | - S de Botton
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France; Inserm UMR1170, Gustave Roussy, Université Paris-Saclay, Villejuif F-94805, France
| | - R-P Desmaris
- Gustave Roussy, Université Paris-Saclay, Département de Pharmacie, Villejuif F-94805, France
| | - J-B Micol
- Gustave Roussy, Université Paris-Saclay, Département d'hématologie, Villejuif F-94805, France; Inserm UMR1170, Gustave Roussy, Université Paris-Saclay, Villejuif F-94805, France.
| |
Collapse
|
20
|
Micol JB, Chahine C, Woerther PL, Ghez D, Netzer F, Dufour C, Merad M, Blot F, Chachaty E, de Botton S, Gachot B. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical? Clin Microbiol Infect 2014; 20:O453-5. [DOI: 10.1111/1469-0691.12445] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 10/11/2013] [Accepted: 11/02/2013] [Indexed: 11/30/2022]
|
21
|
Chahine C, Moukhachen O, Chedid M, Araj GF, Sharara AI. Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori. Am J Health Syst Pharm 2001; 58:1819-23. [PMID: 11596697 DOI: 10.1093/ajhp/58.19.1819] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The efficacy and safety of two ultrashort azithromycin-containing regimens for Helicobacter pylori infection were studied. Patients positive for H. pylori infection were assigned to receive either a three-day drug regimen (group A) or a five-day regimen (group B). In both groups, patients received lansoprazole 30 mg p.o. twice daily on day 1 and, on days 2 and 3, lansoprazole 30 mg p.o. twice daily, amoxicillin 1 g (of anhydrous amoxicillin) p.o. twice daily, and azithromycin 500 mg (of anhydrous azithromycin) p.o. twice daily. Group B patients received lansoprazole 30 mg p.o. twice daily and amoxicillin 1 g p.o. twice daily for two additional days. Gastric biopsy specimens were subjected to culture and susceptibility testing. A minimum of four weeks after the completion of therapy, the patients underwent a 14C-urea breath test to determine whether H. pylori had been eradicated. A total of 28 patients were enrolled (15 in group A and 13 in group B). Treatment was well tolerated. H. pylori was eradicated in 4 (36%) of 11 patients in group A and 2 (22%) of 9 group B patients (26.6% and 15.4%, respectively, in intention-to-treat analysis). None of the isolates of H. pylori showed resistance to amoxicillin or clarithromycin. Regimens consisting of lansoprazole plus two or four days of azithromycin and amoxicillin therapy eradicated H. pylori in 36% and 22% of patients, respectively.
Collapse
Affiliation(s)
- C Chahine
- School of Pharmacy, Lebanese American University, Byblos, Lebanon
| | | | | | | | | |
Collapse
|